SEC Form 4: Randall Mark Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $TCBP alert in real time by email
SEC FORM 4/A SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Randall Mark Edward

(Last) (First) (Middle)
C/O RENAISSANCE CAPITAL PARTNERS LTD
42 SHAD THAMES

(Street)
LONDON X0 SE1 2YD

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TC BioPharm (Holdings) plc [ TCBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/30/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
01/11/2023
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares [ADS] 11/30/2022 P 70,000 A $5 136,834 I By Renaissance Capital Partners Ltd
Ordinary Shares [ADS] 9,952 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Warrants $5 11/30/2022 P 70,000 11/30/2022 05/30/2028 Ordinary Shares 70,000 $0(1) 70,000 I By Renaissance Capital Partners Ltd
Series B Warrants $5 11/30/2022 P 70,000 11/30/2022 05/30/2025 Ordinary Shares 70,000 $0(2) 70,000 I By Renaissance Capital Partners Ltd
Warrants $4.25 04/11/2022 02/10/2028 Ordinary Shares 106,129 106,129 I By Renaissance Capital Partners Ltd
Explanation of Responses:
1. Series A Warrants were issued as part of a unit comprised of one Ordinary Share, one Series A Warrant, and one Series B Warrant, with a purchase price per unit of $5.00.
2. Series B Warrants were issued as part of a unit comprised of one Ordinary Share, one Series A Warrant, and one Series B Warrant, with a purchase price per unit of $5.00.
/s/ Thomas Nicholls 01/11/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $TCBP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCBP

DatePrice TargetRatingAnalyst
More analyst ratings

$TCBP
Press Releases

Fastest customizable press release news feed in the world

See more
  • TCBP Announces Transition from Nasdaq to OTC Markets

    EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

    The company is expected to reduce core operational burn by 55% when compared to 2024EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. 

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

    FDA-approved product in a multi-billion-dollar marketRevenue generation projected in 2025EDINBURGH, Scotland, March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension.

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCBP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TCBP
SEC Filings

See more

$TCBP
Leadership Updates

Live Leadership Updates

See more
  • TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

    EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TC BioPharm Announces New Chair of the Board, Arlene Morris

    EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

    Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm.  Most recently she was with Loxo at Lilly, where

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCBP
Financials

Live finance-specific insights

See more
  • /C O R R E C T I O N -- TC BioPharm/

    In the news release, TCBP Issues 25% Stock Dividend, issued 30-Dec-2024 by TC BioPharm over PR Newswire, we are advised by the company that in the fourth paragraph, both instances of "January 8" should instead read "January 7". The complete, corrected release follows: TCBP Issues 25% Stock Dividend EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCBP Issues 25% Stock Dividend

    EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS he

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

    EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.

    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCBP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more